Guardant Health, Inc. $GH Stock Position Lowered by Aristotle Atlantic Partners LLC

Posted by Francis Steltz on Jun 18th, 2026

Aristotle Atlantic Partners LLC lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 46.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 494,386 shares of the company’s stock after selling 429,348 shares during the period. Guardant Health comprises about 2.3% of Aristotle Atlantic Partners LLC’s investment portfolio, making the stock its 11th biggest holding. Aristotle Atlantic Partners LLC’s holdings in Guardant Health were worth $50,497,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Allworth Financial LP raised its holdings in shares of Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after purchasing an additional 138 shares in the last quarter. Eastern Bank raised its holdings in shares of Guardant Health by 6.9% during the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after purchasing an additional 139 shares in the last quarter. Xponance LLC raised its holdings in shares of Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after purchasing an additional 199 shares in the last quarter. Danske Bank A S raised its holdings in shares of Guardant Health by 20.0% during the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after purchasing an additional 200 shares in the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna raised its holdings in shares of Guardant Health by 1.9% during the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling

In other news, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the sale, the director owned 11,183 shares in the company, valued at $1,420,017.34. The trade was a 47.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the sale, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This represents a 10.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 449,006 shares of company stock valued at $51,148,938. Insiders own 5.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GH. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research note on Thursday, May 21st. The Goldman Sachs Group started coverage on shares of Guardant Health in a research note on Friday, June 5th. They issued a “buy” rating and a $165.00 target price on the stock. Royal Bank Of Canada started coverage on shares of Guardant Health in a research note on Thursday, June 11th. They issued an “outperform” rating and a $185.00 target price on the stock. Finally, Wells Fargo & Company raised their target price on shares of Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $141.95.

Check Out Our Latest Stock Report on Guardant Health

Guardant Health Stock Up 1.4%

Shares of GH stock opened at $129.11 on Thursday. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $135.00. The company has a market capitalization of $17.12 billion, a P/E ratio of -38.09 and a beta of 1.61. The firm has a 50-day moving average price of $105.69 and a 200 day moving average price of $102.51.

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.